Literature DB >> 3720567

Hypertension. Relationship with other risk factors.

W B Kannel.   

Abstract

Elevated blood pressure is a major contributor to cardiovascular disease in general and to coronary heart disease in particular, now its most common sequela. The risk is proportional to the degree of blood pressure elevation, at all ages and in either sex, whether the increased pressure is labile or fixed, diastolic or systolic in character. The effect of blood pressure on cardiovascular disease incidence is independent of the influence of other predisposing co-factors, but the hazard is greatly influenced by them. Elevated pressures are often accompanied by hyperlipidaemia, hyperuricaemia, overweight, hyperglycaemia, elevated fibrinogen values and ECG abnormalities. The risk associated with any degree of elevation of pressure varies greatly, depending on the number and level of these often associated risk factors, and on whether or not there is the indication of target organ involvement. The excess cardiovascular risk in hypertensive persons tends to be concentrated in those with an increased LDL/HDL cholesterol ratio, impaired glucose tolerance, cigarette smokers and those with accompanying ECG abnormalities. Hypertension is best conceptualised as a component of a multivariate cardiovascular risk profile which provides a sound basis for determining urgency for drug treatment. Optimal preventive management of hypertension requires multifactorial correction of all disordered components of the cardiovascular risk profile before occurrence of target organ involvement.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3720567     DOI: 10.2165/00003495-198600311-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  10 in total

Review 1.  Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study.

Authors:  W B Kannel; W P Castelli; T Gordon
Journal:  Ann Intern Med       Date:  1979-01       Impact factor: 25.391

2.  Epidemiology of hypertension.

Authors:  W M Smith
Journal:  Med Clin North Am       Date:  1977-05       Impact factor: 5.456

Review 3.  Interrelationship of sodium, volume, CNS, and hypertension.

Authors:  L J Tobian
Journal:  Prog Biochem Pharmacol       Date:  1983

Review 4.  Role of nutrition in hypertension and its control--experimental aspects.

Authors:  H P Dustan
Journal:  Prog Biochem Pharmacol       Date:  1983

5.  Perspectives on systolic hypertension. The Framingham study.

Authors:  W B Kannel; T R Dawber; D L McGee
Journal:  Circulation       Date:  1980-06       Impact factor: 29.690

6.  Lipoproteins, cardiovascular disease, and death. The Framingham study.

Authors:  T Gordon; W B Kannel; W P Castelli; T R Dawber
Journal:  Arch Intern Med       Date:  1981-08

7.  Labile hypertension: a faulty concept? The Framingham study.

Authors:  W B Kannel; P Sorlie; T Gordon
Journal:  Circulation       Date:  1980-06       Impact factor: 29.690

8.  Incidence and prognosis of unrecognized myocardial infarction. An update on the Framingham study.

Authors:  W B Kannel; R D Abbott
Journal:  N Engl J Med       Date:  1984-11-01       Impact factor: 91.245

9.  Manifestations of coronary disease predisposing to stroke. The Framingham study.

Authors:  W B Kannel; P A Wolf; J Verter
Journal:  JAMA       Date:  1983-12-02       Impact factor: 56.272

10.  Systolic blood pressure, arterial rigidity, and risk of stroke. The Framingham study.

Authors:  W B Kannel; P A Wolf; D L McGee; T R Dawber; P McNamara; W P Castelli
Journal:  JAMA       Date:  1981-03-27       Impact factor: 56.272

  10 in total
  13 in total

1.  First line treatment in hypertension.

Authors: 
Journal:  BMJ       Date:  1991-01-12

Review 2.  Incentive spirometry for preventing pulmonary complications after coronary artery bypass graft.

Authors:  Eliane R F S Freitas; Bernardo G O Soares; Jefferson R Cardoso; Álvaro N Atallah
Journal:  Cochrane Database Syst Rev       Date:  2012-09-12

3.  Comparison of the hemodynamic effects of metoprolol and carvedilol in hypertensive patients.

Authors:  K Weber; T Bohmeke; R van der Does; S H Taylor
Journal:  Cardiovasc Drugs Ther       Date:  1996-05       Impact factor: 3.727

4.  Effect of terazosin on blood pressure and serum lipids.

Authors:  P Gong; J Tang; L Cheng; Z Lu; J Zhang; F Zeng
Journal:  J Tongji Med Univ       Date:  1999

5.  Community control of hypertension at work-site: epidemiological data of the Agusta project.

Authors:  R Fogari; G Marasi; A Zoppi; G D Malamani; A Vanasia; G Villa
Journal:  Eur J Epidemiol       Date:  1995-10       Impact factor: 8.082

Review 6.  Goals of antihypertensive therapy.

Authors:  G E McVeigh; J Flack; R Grimm
Journal:  Drugs       Date:  1995-02       Impact factor: 9.546

Review 7.  A risk-benefit assessment of celiprolol in the treatment of cardiovascular disease.

Authors:  M J Kendall; I Rajman
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

8.  Preliminary clinical experience with calcium antagonists in atherosclerosis. Verapamil in Hypertension Atherosclerosis Study Investigators.

Authors:  B Magnani; C Dal Palù; A Zanchetti
Journal:  Drugs       Date:  1992       Impact factor: 9.546

9.  Blood pressure profile in two adult male populations.

Authors:  H K Wolf; G R Dagenais; J G Fodor; R S Fynes; S P Handa; R B Haynes; G A Klassen; M G Myers; N M Robitaille
Journal:  CMAJ       Date:  1988-09-15       Impact factor: 8.262

10.  Cohort Profile: The Framingham Heart Study (FHS): overview of milestones in cardiovascular epidemiology.

Authors:  Connie W Tsao; Ramachandran S Vasan
Journal:  Int J Epidemiol       Date:  2015-12       Impact factor: 7.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.